A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia

A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia

Introduction: The therapeutic strategy and management of chronic myeloid leukemia (CML) have rapidly improved with the discovery of effective tyrosine kinase inhibitors (TKIs) to target BCR::ABL1 oncoprotein. However, nearly 30% of patients develop TKI resistance due to acquired mutations on the tyr...

Full description

Bibliographic Details
Main Authors: Nittaya Limsuwanachot, Budsaba Rerkamnuaychoke, Pimjai Niparuck, Roongrudee Singdong, Adcharee Kongruang, Piyapha Hirunpatrawong, Thanaporn Siriyakorn, Pa-thai Yenchitsomanus, Teerapong Siriboonpiputtana
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:Journal of Mass Spectrometry and Advances in the Clinical Lab
Subjects:
Mass array
BCR::ABL1 tyrosine kinase domain mutation
JAK2 V617F
MPL W515K/L
CALR mutation
Online Access:http://www.sciencedirect.com/science/article/pii/S2667145X23000238

Internet

http://www.sciencedirect.com/science/article/pii/S2667145X23000238

Similar Items